Adverum Biotechnologies, Inc.
ADVM · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $465 | $0 | $0 | $0 |
| Gross Profit | -$465 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $38,913 | $37,125 | $28,747 | $24,095 |
| G&A Expenses | $9,110 | $12,730 | $19,474 | $38,122 |
| SG&A Expenses | $9,110 | $12,730 | $19,474 | $38,122 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$1,465 | $0 | $0 | $0 |
| Operating Expenses | $46,558 | $49,855 | $48,221 | $62,217 |
| Operating Income | -$47,023 | -$49,855 | -$48,221 | -$62,217 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | -$629 | $664 | $1,202 | $1,687 |
| Pre-Tax Income | -$47,652 | -$49,191 | -$47,019 | -$60,530 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$47,652 | -$49,191 | -$47,019 | -$60,530 |
| % Margin | – | – | – | – |
| EPS | -2.03 | -2.34 | -2.25 | -1.96 |
| % Growth | 13.2% | -4% | -14.8% | – |
| EPS Diluted | -2.03 | -2.34 | -2.25 | -1.96 |
| Weighted Avg Shares Out | 23,487 | 21,010 | 20,938 | 20,898 |
| Weighted Avg Shares Out Dil | 23,487 | 21,010 | 20,938 | 20,898 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $465 | $535 | $683 | $810 |
| EBITDA | -$47,187 | -$49,320 | -$47,538 | -$61,407 |
| % Margin | – | – | – | – |